# To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Source: https://onco.cc/trials/nct06072131/  
OnCo record `nct06072131` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Belinostat and Pralatrexate in peripheral T-cell lymphomas, run by Acrotech Biopharma Inc., now recruiting.

## Summary

To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL is a phase 3 interventional study registered as NCT06072131 by Acrotech Biopharma Inc., with 504 participants planned, started 2023-10-04 and due to reach its primary completion in 2030-07. Interventions recorded: Belinostat Injection, Pralatrexate Injection, CHOP and COP.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06072131
- Phase: 3
- Setting: A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients With Peripheral T-Cell Lymphoma
- Sponsor: Acrotech Biopharma Inc.
- Enrolled: 504

## Sources

- ClinicalTrials.gov NCT06072131: https://clinicaltrials.gov/study/NCT06072131

## Connected records

- cancers: [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/)
- drugs: [Belinostat](https://onco.cc/drugs/belinostat/), [Pralatrexate](https://onco.cc/drugs/pralatrexate/)
- companies: [Acrotech Biopharma](https://onco.cc/companies/acrotech-biopharma/)

---
JSON: https://onco.cc/api/v1/entities/nct06072131.json